A study of AEOL 10150 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2016
At a glance
- Drugs AEOL 10150 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 21 Dec 2016 According to an Aeolus Pharmaceuticals media release, the U.S. Food & Drug Administration received clearance to initiate phase I studies with AEOL 10150 in healthy normal volunteers.
- 15 Aug 2016 According to Aeolus Pharmaceuticals media release, planned initiation date changed from 1 Jul 2016 to 1 Jul 2017.
- 15 Aug 2016 According to Aeolus Pharmaceuticals media release, company is preparing for IND submissions to the FDA and initiating clinical study over the next two quarters.